Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, and the nine-month period ended on the same date for Becton, Dickinson and Company (BD). BD is a global medical technology company organized into three reportable segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. The company reported 258,544,900 shares of common stock outstanding as of July 31, 2001.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 | Nine Months Ended June 30, 2001 |
|---|---|---|
| Revenues | $954.2 million | $2,758.6 million |
| Net Income | $124.3 million | $303.3 million |
| Diluted EPS | $0.46 | $1.13 |
| Operating Margin | 18.6% | 16.7% |
| Gross Profit Margin | 50.2% | 48.8% |
| Operating Cash Flow (9mo) | $524.5 million | |
| Total Debt | $1.31 billion (Short-term: $539.4M; Long-term: $772.7M) | |
| Cash and Equivalents | $71.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 4% for the quarter and 2% for the nine months compared to the prior year. Growth was unfavorably impacted by foreign currency translation (reducing revenue by ~2-4%) and economic conditions in Latin America and Asia Pacific.
- Segment Performance:
- Medical Systems: Revenues up 2% (5% excluding currency), driven by advanced protection devices and insulin syringes.
- Clinical Lab: Revenues up 6% (8% excluding currency), aided by advanced protection devices and a favorable comparison to prior year distributor inventory shifts.
- Biosciences: Revenues up 11% (13% excluding currency), with growth across all product groups.
- Profitability: Operating income increased to $177.1 million for the quarter (up from $151.3 million) and $460.5 million for the nine months (up from $422.9 million). Operating margins improved due to lower operating expenses as a percentage of revenue.
- Interest Expense: Net interest expense declined $4 million for the quarter and $13 million for the nine months due to lower debt levels and interest rates.
- Investment Gains: Unlike the prior year, which included significant gains on investment sales ($31.8M for the quarter, $64.9M for nine months), the current period reported no such gains.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year capital spending to be approximately $376 million, similar to the prior year. The effective tax rate is expected to be about 24% for the full year.
- Future Sales Trends: The company intends to redirect promotional efforts in the U.S. Medical segment toward retail-level branded syringe sales and the pen needle market. This shift is expected to result in lower U.S. Medical segment sales in the fourth quarter.
- Accounting Changes: BD is adopting SAB No. 101 (Revenue Recognition) in the fourth quarter of fiscal 2001, expecting a cumulative effect adjustment but no material impact on results. The company is also evaluating SFAS No. 141 and 142 regarding business combinations and goodwill, with adoption required by October 1, 2002.
- Risks and Contingencies:
- Legal Proceedings: BD faces ongoing litigation regarding latex glove allergies (466 claims to date) and a patent infringement suit filed by Retractable Technologies, Inc. regarding safety syringes. A CalOSHA citation regarding the BD Eclipse blood collection device is under appeal.
- Restructuring: The company continues to execute restructuring plans initiated in 1998, 1999, and 2000. The closure of the Hancock, NY surgical blade plant is now expected to be completed by December 2002.
- Market Risks: Exposure to foreign currency fluctuations, interest rate changes, and competitive pricing pressures remains a key risk factor.
Investor Verification Checklist
- Verify the impact of the upcoming adoption of SAB No. 101 on revenue recognition in the fourth quarter.
- Monitor the status of the Retractable Technologies, Inc. litigation and the CalOSHA citation regarding the Eclipse device.
- Assess the timeline and cost implications of the delayed closure of the Hancock, NY facility (now expected late 2002).
- Review the fourth-quarter sales forecast for the U.S. Medical segment, which management expects to decline due to promotional strategy shifts.
- Confirm the realization of estimated annual savings ($30M from 2000 plan, $6M from 1999 plan) against incremental costs for new product initiatives.